共 18 条
[2]
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients[J] Armitage The New England Journal of Medicine 2014,
[3]
The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.[J] Li Xiang-ping;Gong Hai-rong;Huang Xian-sheng;Huang Wen-yu;Zhao Shui-ping Lipids in health and disease 2013,
[4]
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm; open-label; phase 3 study[J] Marina Cuchel;Emma A Meagher;Hendrik du Toit Theron;Dirk J Blom;A David Marais;Robert A Hegele;Maurizio R Averna;Cesare R Sirtori;Prediman K Shah;Daniel Gaudet;Claudia Stefanutti;Giovanni B Vigna;Anna ME Du Plessis;Kathleen J Propert;William J Sasiela;LeAnne T Bloedon;Daniel J Rader The Lancet 2013,
[5]
Mipomersen; an Apolipoprotein B Synthesis Inhibitor; Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk[J] Gregory S. Thomas;William C. Cromwell;Shariq Ali;Wai Chin;JoAnn D. Flaim;Michael Davidson Journal of the American College of Cardiology 2013,
[6]
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design; pre-specified muscle and liver outcomes; and reasons for stopping study treatment.[J] ;Richard Haynes;Lixin Jiang;Jemma C Hopewell;Jing Li;Fang Chen;Sarah Parish;Martin J. Landray;Rory Collins;Jane Armitage;R. Collins;J. Armitage;C. Baigent;Z. Chen;M. Landray;Y. Chen;L. Jiang;T. Pedersen;M. Landray;L. Bowman;F. Chen;M. Hill;R. Haynes;C. Knott;K. Rahimi;J. Tobert;P. Sleight;D. Simp
[7]
n-3 fatty acids in patients with multiple cardiovascular risk factors.[J] Roncaglioni Maria Carla;Tombesi Massimo;Avanzini Fausto;Barlera Simona;Caimi Vittorio;Longoni Paolo;Marzona Irene;Milani Valentina;Silletta Maria Giuseppina;Tognoni Gianni;Marchioli Roberto The New England journal of medicine 2013,
[8]
Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe.[J] Taylor Allen J;Villines Todd C;Stanek Eric J European heart journal 2012,
[9]
Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects.[J] Cicero Arrigo F G;Reggi Alessandra;Parini Angelo;Borghi Claudio Archives of medical science : AMS 2012,
[10]
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.[J] Boden William E;Probstfield Jeffrey L;Anderson Todd;Chaitman Bernard R;Desvignes-Nickens Patrice;Koprowicz Kent;McBride Ruth;Teo Koon;Weintraub William The New England journal of medicine 2011,